EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Newsletter

Sources

Dose Diligence research deskSection 10 · Page 15 of 15Last updated 17 Nov 2026

Weekly briefing

  1. CDC — GLP-1 use and modified medication use; November 12, 2026. https://www.cdc.gov/mmwr/volumes/75/wr/mm7544a1.htm
  2. FDA — GLP-1 safety-labelling communication; November 9, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
  3. FDA — DSCSA exemptions. https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
  4. NABP Pulse — Closing the gaps in DSCSA compliance. https://pulse.pharmacy/resources/newsroom/closing-the-gaps-in-your-dscsa-compliance-program/
  5. NovoCare — Provider home-delivery programme. https://www.novocare.com/hcp/delivery.html

Monthly digest

  1. Lilly — Hims & Hers agreement; November 6, 2026. https://investor.lilly.com/node/55266/pdf
  2. Walgreens — Expanded weight-management services; October 27, 2026. https://corporate.walgreens.com/news-and-stories/press-releases/pharmacy-healthcare/walgreens-expands-access-to-weight-management-care-and-introduces-new-glp-1-support-services/
  3. LillyDirect — Zepbound presentations and prices. https://www.lilly.com/lillydirect/zepbound
  4. NovoCare — Wegovy savings offers. https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
  5. LillyDirect — Foundayo prices and conditions. https://www.lilly.com/lillydirect/foundayo
  6. FDA — RonanRx warning letter; October 30, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ronanrx-inc-dba-ronanrx-737905-10302026
  7. FDA — GLP-1 compounding policy clarification; April 1, 2026 update. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  8. Fifth Circuit — Semaglutide shortage litigation opinion; September 1, 2026. https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10758/pdf/USCOURTS-ca5-25-10758-0.pdf
  9. California Board of Pharmacy — Nonresident pharmacy licensing. https://www.pharmacy.ca.gov/applicants/phy.shtml
  10. California Board of Pharmacy — New nonresident pharmacy requirements. https://www.pharmacy.ca.gov/applicants/new_requirements_nrp.shtml

Quarterly outlook and FAQ support

  1. Novo Nordisk — Scheduled January 2027 list-price reduction; February 24, 2026 announcement. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916504
  2. CMS — Medicare GLP-1 Bridge information for providers. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
  3. CMS — Medicare GLP-1 Bridge information for Part D plans. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
  4. Medicare — Weight-loss drug coverage. https://www.medicare.gov/coverage/weight-loss-drugs
  5. FDA — Proposed exclusion of three substances from the 503B bulks list; April 30, 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  6. FDA — Concerns with unapproved GLP-1 drugs. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  7. LillyDirect — Patient-access and dispensing FAQ. https://www.lilly.com/lillydirect/faq
  8. Federal Register — 503B proposal and statutory background; May 1, 2026. https://www.govinfo.gov/content/pkg/FR-2026-05-01/pdf/2026-08552.pdf
  9. FDA — Ready Med warning letter, including clarification of registration versus approval; June 8, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ready-med-730317-06082026

Sources cited on this page

  1. cdc.gov · Source 1 ↗https://www.cdc.gov/mmwr/volumes/75/wr/mm7544a1.htm
  2. fda.gov · Source 2 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
  3. fda.gov · Source 3 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
  4. pulse.pharmacy · Source 4 ↗https://pulse.pharmacy/resources/newsroom/closing-the-gaps-in-your-dscsa-compliance-program/
  5. novocare.com · Source 5 ↗https://www.novocare.com/hcp/delivery.html
  6. investor.lilly.com · Source 6 ↗https://investor.lilly.com/node/55266/pdf
  7. corporate.walgreens.com · Source 7 ↗https://corporate.walgreens.com/news-and-stories/press-releases/pharmacy-healthcare/walgreens-expands-access-to-weight-management-care-and-introduces-new-glp-1-support-services/
  8. lilly.com · Source 8 ↗https://www.lilly.com/lillydirect/zepbound
  9. novocare.com · Source 9 ↗https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
  10. lilly.com · Source 10 ↗https://www.lilly.com/lillydirect/foundayo
  11. fda.gov · Source 11 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ronanrx-inc-dba-ronanrx-737905-10302026
  12. fda.gov · Source 12 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  13. govinfo.gov · Source 13 ↗https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10758/pdf/USCOURTS-ca5-25-10758-0.pdf
  14. pharmacy.ca.gov · Source 14 ↗https://www.pharmacy.ca.gov/applicants/phy.shtml
  15. pharmacy.ca.gov · Source 15 ↗https://www.pharmacy.ca.gov/applicants/new_requirements_nrp.shtml
  16. novonordisk.com · Source 16 ↗https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916504
  17. cms.gov · Source 17 ↗https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
  18. cms.gov · Source 18 ↗https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
  19. medicare.gov · Source 19 ↗https://www.medicare.gov/coverage/weight-loss-drugs
  20. fda.gov · Source 20 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  21. fda.gov · Source 21 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  22. lilly.com · Source 22 ↗https://www.lilly.com/lillydirect/faq
  23. govinfo.gov · Source 23 ↗https://www.govinfo.gov/content/pkg/FR-2026-05-01/pdf/2026-08552.pdf
  24. fda.gov · Source 24 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ready-med-730317-06082026
Section sources →